HC Wainwright Decreases Earnings Estimates for MediWound

MediWound Ltd. (NASDAQ:MDWD) – Investment analysts at HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for shares of MediWound in a report released on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings per share of $3.11 for the year, down from their previous estimate of $3.21. HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.75) per share.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.42. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $3.37 million. MediWound had a negative return on equity of 68.75% and a negative net margin of 180.30%.During the same period last year, the firm earned ($0.07) EPS.

MDWD has been the topic of several other reports. Wall Street Zen downgraded MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Oppenheimer reaffirmed an “outperform” rating and set a $32.00 price target (down from $33.00) on shares of MediWound in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $34.00.

MediWound Stock Performance

Shares of MDWD opened at $14.56 on Friday. The business’s 50-day moving average is $16.68 and its two-hundred day moving average is $17.46. The company has a market capitalization of $187.10 million, a P/E ratio of -6.44 and a beta of 0.21. MediWound has a fifty-two week low of $14.14 and a fifty-two week high of $22.50.

Institutional Investors Weigh In On MediWound

Several institutional investors have recently bought and sold shares of MDWD. Rosalind Advisors Inc. boosted its holdings in MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after buying an additional 341,993 shares during the last quarter. Kotler Kevin acquired a new stake in MediWound in the 4th quarter worth about $6,225,000. Millennium Management LLC boosted its holdings in MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after buying an additional 136,884 shares during the last quarter. UBS Group AG boosted its holdings in MediWound by 90.1% in the 4th quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after buying an additional 68,756 shares during the last quarter. Finally, Menora Mivtachim Holdings LTD. boosted its holdings in MediWound by 348.8% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after buying an additional 61,039 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.